Welcome to our dedicated page for Semnur Pharmaceuticals SEC filings (Ticker: SMNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Semnur Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Semnur Pharmaceuticals's regulatory disclosures and financial reporting.
Scilex Holding Company filed an amended Schedule 13D showing continued majority ownership of Semnur Pharmaceuticals after a stock dividend. Scilex is deemed to beneficially own 181,520,112 shares of Semnur common stock, representing 78.85% of the outstanding class based on 230,209,142 shares.
Including 5,423,606 shares of Series A Preferred Stock that vote with common stock, Scilex’s aggregate holdings represent 79.34% of total voting power. On June 15, 2026, Scilex and its subsidiaries distributed 7,034,737 Semnur common shares as a dividend to Scilex stockholders and other eligible equity holders of record as of June 1, 2026.
Scilex Holding Co, a major holder of Semnur Pharmaceuticals, Inc., reported a previously announced stock dividend of 13,972,900 shares of Semnur common stock distributed to its own common shareholders and certain warrant and convertible note holders as of a June 1, 2026 record date.
The filing notes that 6,938,163 of these dividend shares are being held in abeyance for additional participating warrant and note holders, to be distributed if and when those instruments are exercised or converted, with a separate Form 4 to be filed at that time. The report also shows a J-code restructuring entry for 7,034,737 Semnur common shares at a stated price of $0.0000 per share and updated direct and indirect ownership positions, including shares held through Scilex, Inc. and Scilex Bio, Inc.
Semnur Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 25, 2026. Stockholders representing 5,423,606 shares of Series A preferred stock and 200,307,471 shares of common stock, or about 87% of common shares outstanding as of April 28, 2026, were present virtually or by proxy.
Stockholders elected Jay Chun, M.D., Ph.D. as a Class I director to serve until the 2029 annual meeting. They also ratified Pipara & Co LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved both the 2025 Equity Incentive Plan and the 2025 Employee Stock Purchase Plan.
Semnur Pharmaceuticals, Inc. reports a larger quarterly loss and severe liquidity pressure in its latest period. For the three months ended March 31, 2026, the company recorded a net loss of $4.6 million, up from $0.7 million a year earlier, as research and development and general and administrative expenses increased to $4.6 million in total.
Semnur ended the quarter with only $0.1 million in cash and cash equivalents and total assets of $2.0 million, against total liabilities of $27.3 million, resulting in a stockholders’ deficit of $25.3 million. Operating activities used $2.7 million of cash, which was offset by $2.8 million of net financing inflows, primarily related party loans and partial repayment of promissory notes.
The company terminated both a planned $20.0 million PIPE equity financing and a proposed $100.0 million Bitcoin-funded share purchase agreement in April 2026, leaving it reliant on Scilex Holding Company for services and funding while it advances its lead late-stage pain candidate SP-102. Management states that recurring losses, minimal cash, dependence on Scilex and the need for additional financing raise substantial doubt about Semnur’s ability to continue as a going concern.
Semnur Pharmaceuticals, Inc. filed Post-Effective Amendment No. 1 to its Form S-1 to update its shelf registration and include information from its Form 10-K for the year ended December 31, 2025. The amendment does not register additional securities.
The prospectus registers: up to 203,737,349 shares of Common Stock for resale by selling securityholders; up to 7,432,122 shares issuable upon exercise of warrants; and up to 510,000 Private Warrants. The company will receive proceeds only from any warrants exercised for cash. The filing also discloses consolidated results through December 31, 2025, including net losses of $160.4 million for 2025 and an accumulated deficit of $275.8 million as of that date.
Semnur Pharmaceuticals, Inc. disclosed that it has terminated two previously agreed equity financing arrangements tied to its deSPAC business combination. Under a Securities Purchase Agreement with JW Capital Securities Limited, Semnur had planned to sell 1,250,000 common shares at $16.00 per share but no shares were ever issued. A separate Securities Purchase Agreement with Biconomy PTE. Ltd. for 6,250,000 common shares at $16.00 per share, payable in Bitcoin, was also terminated. Both agreements were ended effective April 20, 2026, leaving the company without the equity capital those PIPE transactions were intended to provide.
Semnur Pharmaceuticals, Inc. announced that Chief Executive Officer and President Jaisim Shah retired and resigned from his roles and from the board effective March 13, 2026. His departure is stated not to result from any disagreement with the company. Under a separation agreement, he will receive six months of continued base salary at an annual rate of $1,250,000 and a 90‑day extension to exercise vested stock options, and his prior employment agreement was terminated with a general release of claims.
The board reduced its size from six to five directors and appointed Henry Ji, Ph.D. as Chief Executive Officer and President effective at the same time, without changing his compensation. The board also appointed Stephen Ma as Chief Operating Officer effective March 17, 2026, with no change to his compensation, while he continues as Chief Financial Officer and Secretary.
The filing also summarizes related‑party arrangements with controlling stockholder Scilex Holding Company, including a transition services agreement under which Scilex provides various support services with total costs capped at $2.0 million per year for three years, and a $806,366.78 promissory note owed to the SPAC sponsor, payable in six monthly installments and subject to acceleration upon certain equity or debt financings or events of default.